AU2006235980B9

AU2006235980B9 - HIV peptides, antigens, vaccine compositions, immunoassay kit and a method of detecting antibodies induced by HIV

Info

Publication number: AU2006235980B9
Application number: AU2006235980A
Authority: AU
Inventors: Birger Sorensen
Original assignee: Bionor Immuno AS
Current assignee: Bionor Immuno AS
Priority date: 1999-03-04
Filing date: 2006-11-13
Publication date: 2009-03-26
Anticipated expiration: 2020-03-02
Also published as: AU2006235980A1; AU2006235980B2; AU2006235987B2; AU2006235987A1

Description

AUSTRALIA

Patents Act COMPLETE SPECIFICATION

(ORIGINAL)

Class Int. Class Application Number: Lodged: Complete Specification Lodged: Accepted: Published: Priority Related Art: Name of Applicant: Bionor Immuno AS Actual Inventor(s): Birger Sorensen Address for Service and Correspondence: PHILLIPS ORMONDE FITZPATRICK Patent and Trade Mark Attorneys 367 Collins Street Melbourne 3000 AUSTRALIA Invention Title: HIV PEPTIDES, ANTIGENS, VACCINE COMPOSITIONS, IMMUNOASSAY KIT AND A METHOD OF DETECTING ANTIBODIES INDUCED BY HIV Our Ref 786723 POF Code: 1189/457707 The following statement is a full description of this invention, including the best method of performing it known to applicant(s): HIV peptides, antigens, vaccine compositions, immunoassay kit and a method of S detecting antibodies induced by HIV s The present invention relates to novel peptides based on conserved regions of HIV gag O p24, antigens in free or carrier-bound form comprising' at least one of the said peptides, vaccine compositions containing at least one of the antigens, immunoassay kits and a.

method of detecting antibodies, induced by human immunodeficiency virus (HIV) or S HIV-specific peptides, using such antigens.

BACKGROUND

'There is an urgent need to control the global epidemic of HIV infection and the is development of a vaccine against HIV is one of the major objectives in AIDS research.

In general vaccines should activate antigen presenting cells, overcome genetic restriction in T-cell responses and generate T- and B-memory cells. The variability of the viral population poses a further difficulty in obtaining an effective HIV vaccine. A break through in the ongoing attempts to develop a vaccine against AIDS has so far not been reported. It is now generally accepted that an induction of antigen-specific humoral and cell-mediated immunity is crucial for a development of an effective prophylactic and therapeutic vaccine. All three arms of the immune system including neutralizing antibodies; CD8+CTL and T-helper-1 (TH1) cells might be required for protective immunity to HIV. It is known that CTL can clear other viral infections (Ada, 2s Immunol. Cell Biol., 72:447-454, 1994) and that CTL can lyse infected targets early.in infection before viral progeny can be produced and released by cell lysis, Ada et al., supra.The focus has been on selection of antigens as well as on design and evaluation of different adjuvahces. The antigens used in different in vitro and in vivo studies have been all from crude proteins to various synthetic peptides mainly from gp160 and to some extent from p24. A large number of studies have been done on the V3 loop of gp120. Induction of both B- and T-cell responses have been observed, however, it has been reported from an in vitro study that a peptide from the conserved region of gp41 have indicated infection enhancement Bell et al., Clin. Exp. Immunol., 87 37- (January 1992).

0 Naturally occurring HIV sequences in vaccine candidates are not capable of stimulating a stable immune response due to the viruses inherent ability to hide by changing the S appearance of the epitopes presented on the cell surface of infected cells. The immune s system is fooled to believe that a particular amino acid sequence is relevant when in oo fact the amino acids of importance is hidden.

N A resent study of titers of antibodies against the gag p24 protein, has shown that slow progression towards development of AIDS is associated with high titers, while fast I0 progression towards development of AIDS is associated with low titers. It is shown that persons with low p24 antibody titer develop significantly faster AIDS than persons with high p24 antibody titers (Zwart et al. Virology, 201, p. 285-93, June 1994), indicating that p24 can play a key role to control the development of AIDS.

Is New HIV p24 peptides are described in W091/13360, wherein the peptides are used in a method of discriminating between a false and true diagnosed HIV-positive serum sample.

Johnson et al., The Joural of Immunology, Vol.147, p.1512-1521. September 1, 1991 describe an analysis of the fine specificity of gag-specific CTLresponses in three HIV-1 seropositive individuals, the gag-specific CTL-responses were.

found to be mediated by CD3+CD8+ lymphocytes which are HLA class I restricted.

EP-A-0 356 007 discloses antigenic determinants, in particular it relates to synthetic polypeptide sequences which are related to proteins present in the HIV-1 and which can be used as a basis for a potential vaccine against AIDS.

Rosenberg E.S. et al., Science, Vol.278, 21 November 1997, p.1447-1450 describe that virus specific CD4+ T helper lymphocytes are critical to the maintenance of effective immunity in a number of chronic viral infections, but are characteristically undetectable in chronic human immunodeficiency virus-type 1 (HIV-1) infection. HIV-1specific proliferative responses to p24 were inversely related to viral load. They 3

O

CN conclude that the HIV-1-specific helper cells are likely to be important in O immunotherapeutic interventions and vaccine development EP 0230 222, EP 0 270 114, DE 37 11 016 and GB 2 188 639 all in the name of F.

s Hoffmann-La Roche Co. Aktiengesellschaft concern recombinant expression and 00 purification of an HTLVIII Gag/Env gene protein or fusionproteins. The proteins n consisting of native sequences can be purified to homogeneity and used as a basis for CN diagnostic tests for detection of antibodies against viruses associated with AIDS. The Sgag/env protein may also be formulated for use as a vaccine for protection against l to AIDS through prophylactic immunization.

From a diagnostic and therapeutic point of view, the major problems with using p24 as part of an assay or therapy is associated with the high number of epitopes on p24 which stimulates production of a large number of antibodies with poor specificity, which is through repeated boostering on potential mutated sequences can create autoantibodies (Autoantibodies to the alfa/beta T-cell receptors in HIV infection; dysregulation and mimicry. Lake et al., Proc. Natl. Acad. Sci. USA, 10849-53, Nov. 8 1994).

Further, it is reported that the p24 antibody titer does not reach the same high levels as for the envelope proteins (gp120 and gp41). Normally antibodies to p24 are developed in the very early phase of the infection, but the titer is fairly quickly stabilized after the initial infection period. Later the p24 titer is gradually decreasing while the opposite happens with gp160. These findings can also be seen in relation to recent reports stating that cytotoxic T-cell activity is antagonized by naturally occurring HIV-1 gag variants (Klenerman et al., Nature, 2:369 (6479), p. 355, 2 June 1994). This can be one of the reasons why a rapid stabilization of the p24 titer is seen and why it later starts to decrease.

Based on the above background data, we decided to investigate the possibility of designing novel synthetic peptides which can mimic the p24 epitope without 3o antagonizing the cytotoxic T-cell activity, in order to meet the need for an effective prophylactic and therapeutic vaccine.

INO 4 The intbtl work was based on one epitope which was published by Korber 13., et at..

0 Human Retroviruses and AIDS 1987 Eds..Theoretica Biology and Biophysics Groupi Z Los Alamos National Laboratory. Los Alamos. NtA The amino acid -sequence of this epitope (203-222) was., 0 Lj: AG PGATLEEMM T ACQGVG inRRM RTK SIKO LSSS R R' G VR V S A S E 0Q The one Ltter as well as the three letter codes defiing the amino acids In the.

seuece gve troghout this specification av nacrac ith Intrational .standarfs and gien in textboks, for istance LehninSerA.L, 4[P!dple of Bloclhmitrys. Wort Publishers Inc.. New York 1982. The arninoacids given below the head sequence represent the'natural variation of the sequence. An Initial study of a sequence containing ti modified eptope was conducted on the sequence.: AN PDC KQ I LKSLG PGATLEEXXTACQGVG..

NH

2 wherein X Indicates 2-aminohexanoic acid and the cysteine residues are in an oxidized state. I.e. are forming an Intrachain disulphide bridge. The result *:(unpubflshed) from studies using this peptide as part of a diagnostic kit. showed that the specificity became 87% (n=279) on a preseleted panel of African sera. The sensitivity was surprisingly 1 00% on a panel of HIV-1 positive sera including HIV-1 subtype 0 s era, which is quite different from the other subtypes.

In order to improve specificity, ILe. define the amino acids which contribute to a pure non-crossreacting antibody response. a similar study was applied to a significantly shorter and further modified peptide: LIW GAT C QEH XTAC QG VG-NH2

II

o wherein X has the above mentioned meaning and the cysteine residues are forming an S intrachain disulphide bridge.

The results from this study showed that the specificity of the assay increased to 96%, 0 and (n=293) which is similar to the specificity obtained in the assay without using the p24 peptide. With a specificity of 87% to the assay where the first peptide was included, it would be likely that the peptide would induce immune response to more than one' i0 epitope since it was recognized by unspecific antibodies, if it was used as a vaccine candidate. The latter, however, show that the peptide sequence is picking up an immune response which is unique to HIV-1. Consequently, if a sequence based on this is used as an antigen in a vaccine candidate, it would most likely boost an unique immune response to HIV-1.

To further increase the number of T-cell epitopes and reduce the probability for development of escape mutants three additional peptide sequences were based on the following three sequences from residues 264-284, 253-271 and 166-186, respectively published in Human Retroviruses and AIDS 1997; A Compilation and Analysis of Nucleic Acid and Amino Acid Sequences. Eds.Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos RWI IL GLNKI VRMYSPT S ILD KGV VM M K C VG E D M V V Q I G

S

A

NNP P I PVGE I YKRWI ILGL S QAV KDMLRKGMVM G GSN KV D V V H GT

A

P

6

(O

.and c pEV IPMFSALSEGATPQDLNT R I TT T LTE AD I S YNIYM SLN AL V H V I 00 SM L A m 10

V

O Several modified peptides have been synthesized in order to determine unique sequences which are both specific and sensitive towards HIV-1.

The discussion of documents, acts, materials, devices, articles and the like is included in this specification solely for the purpose of providing a context for the present invention. It is not suggested or represented that any or all of these matters! formed part of the prior art base or were common general knowledge in the field relevant to the present invention as it existed in Australia before the priority date of each claim of this application.

The present invention provides a peptide derived from HIV gag p24 protein, wherein the peptide comprises a modified amino acid sequence containing modifications compared to the native sequence and selected from the groups of amino acid sequences: Xaai Xaa2 Xaa3 Xaa4 Xaas Gly Leu Asn Pro Leu Val [Glyl, Xaa2 Xaa 1 3 Tyr Xaas Pro Xaair Xaase He Leu Xaa 2 1 Xaa2 (SEQ ID NO: 4) wherein the amino adds of the chain have the following meaning; Xaa in position 1 is Arg, Lys. Asp or none Xaa in position 2 is Trp, Gly, Lys or Arg, Xaa in position 3 is lie, Leu, Val or Met, Xaa in position 4 is lie, Val or Leu, Xaa in position 5 Leu, Met, Val or Pro, Xaa in position 12 is Arg, Lys, Xaa in positon 13 is Met or Leu, Xaa in position 15 is Ser, Cys or Gin, Xaa in position 17 is Thr, Val, lie, Ser or Ala, Xaa in position 18 is Ser, Gly or Thr, Xaa in position 21 is Asp, Glu, Cys or Gly, Xaa in position 22 is Gly or nbne, wherein n 0, 1, 2 or 3, Xaal Xaa 2 Xaa 3 Pro lie Pro Xaa 7 Xaa 8 Xaag Xaao 1 Xaall Xaa 12 [Gly]n Xaa 1 3 Xaa,4 Xaa 1 5 Xaa 1 6 Xaai 7 Xaai Xaa 9 l Xaa 20 Xaa 21 Xaa 22 Xaa 23 Xaa 2 4 (SEQ ID NO 9) wherein the Xaa in position 1 is Asn, Ser, Gly, His, Ala, Pro, Arg or none, Xaa in position 2 is Asn, Ala or Lys, Xaa in position 3 is Pro, Gin, Gly, lie or Leu, Xaa in position 7 is Val or Ala, Xaa in position 8 is Gly or Lys, Xaa in position 9 is Glu, Asp, Lys, Phe or Thr, Xaa in position Xaa in position Xaa in position Xaa in position Xaa in position Xaa in position Xaa in position Xaa in position Xaa in position Xaa in position Xaa in position Xaa in position Xaa in position 10 is lie, Met, Val or Leu, 11 is Tyr, Leu or none, 12 is Ser or none, 13 is Arg or none, 14 is Asp, Arg, Trp, Ala or none, 15 is lie or none, 16 is Tyr or none, 17 is Lys or Arg, 18 is Arg, Lys or Asp, 19 is Trp or Gly 20 is lie, Met, Val, Gin or Ala 21 is lie, Val or Ala 22 is Leu, Met or Val Xaa in positon 23 is Gly or Cys Xaa in position 24 is Leu or none W ocumenlsDo Nol Delete\Do not delete 200gnondnenltSRN7BG723 I SPA 210109 0oc .6b v~wherein t seuence of SEQ ID NO. :9 o~tsists 'of at least 0Cx Cnsecujve ao adds NO ~and n 1.2 cx3, and Xaa Xaa2 Be Ie Xaa 5 X;a 6 XaagXaa6 Xaav Ljeu Xaa 11 [Gybj ,)(AgiCaa 1 2 X=3~ 1 Xaa 1 4 Xz*is Xaa,~titX aau XOaait Xa~a XaztXaazzXaa0s yXaaaS M-{8 ID N0:16-) wherein toe Xaa In Positon I is Pro. Lys, Aig or none Xaa in position 2is Gtu.Arg, Phe or Lys t Xain posiUo 6 Is ftWror Nieu IND Anaaipositioi7 is Phe orLau.

Xn Wte8Is W A a or Met c-Ia XaIPWAW 9 nIsAja GAU or LOU Xaa n ositw 11 ft Ser ornone Xaa IposIon 12b Al.Arg, oroe Xs os i 13 Is k Lzu or none xaaposon4 s er. Aa. Lu ornon Xaa ipsM 5s Tyr. Guor Asp X=a i positio 16 Is Gly or Asp Xa pon 17 is ft or Leu Xaa in Posln 18 Is br, go. Vat, Leo or-Asn,' s Pro lbr-or er Xaa in, posltIm20 IsTyr Phe Nieu. Hs or Gin Xaa In Positon 21 Is Asp. Asn. Leu or Ala MainPoto~n22is Lu.1e, Valor Asit Xaa in position 23 Is Asn, Tyr. Gys or Gty Xaa In Position 24 is lbr. Met W. Ala, Val or none XaaIn poston 25lIs Gly or none whereliate sequenc of SEQ 10NO: ISconsiss of at least si onscm riveko acids, n =1,2 or 3 an=0, 1 2 or 3 ndependent of each other.

the terminal ends of the sequences may be free carboxyl- or amino groups, amides.

acyls. acetyls or salts thereof, two or more of fte Cys residues may form part of an Intrachain- or interchain disutphide binding. a -S-(CH 2 or a (CHz 2 )$xidge wherein p =1-8 optiona~y intervened -by one

NO

Sor more heteroatoms such as O, N and S and/or the said peptide sequences are immobilized to a solid support.

Z Throughout the description and claims of this specification, the word "comprise" and variations of the word, such as "comprising" and "comprises", is not intended to exclude other additives, components, integers or steps.

00 N DESCRIPTION OF THE INVENTION s The peptides according to the invention are originating from the four different conserved areas of the HIV-1 core protein p24 which are described above, having the properties of maintaining the uniqueness (sensitivity and specificity) of the HIV-1-epitope. Further the new peptides according to the invention possess no recognized cytotoxic T lymphocyte (CTL) antagonistic effect and shall have at least one potential CTL epitope.

I

The peptides, according to the invention, which have met the above criteria are selected from the following groups; Xaa, Xaa 2 Xaa 3 Xaa 4 Xaa, Xaa, Ala Xaa, Xaa, Gin Thr Pro Trp Xaa 4 Xaa,, Xaa,, Xaa,, XaaeVal Xaa2 (SEQ ID NO: 1) wherein the amino acids of the chain could have the following meanings; Xaa in position 1 of the peptide derivate is Lys or Arg, Xaa in position 2 is Ala, Gly, Ser or Arg, Xaa in position 3 is Leu or Met,.

Xaa in position 4 is Gly or Arg, Xaa in position 5 is Pro, Thr, Val, Ser, Gin or Ala, Xaa in position 6 is Gly, Ala, Lys, Arg, Gin or Glu, Xaa in position 8 is Thr or Ser, Q Xaa in position 9 is Leu or lie, g Xaa in position 14 is Thr, Ser or Val, SXaa in position 15 is Ala or Ser, Xaa in position 16 is Cys or Ser, Xaa in position 17 is Gin or Leu Xaa in position 18 is Gly, Glu or Arg, 00 0Xaa in position 20 is Gly or Arg, In c 10 the peptide comprises at least nine consecutive amino acids of the sequence of SEQ SID NO 1, Xaal Xaa 2 Xaa 3 Xaa 4 Xaas Gly Leu Asn Pro Leu Val [Gly]n Xaa 12 Xaa,3 Tyr Xaa 15 Pro Xaa 17 Xaa 8 i lie Leu Xaa 2 Xaa 2 2 (SEQ ID NO: 4) wherein the amino acids of the chain have the following meaning: Xaa in position 1 is Arg, Lys, Asp or none Xaa in position 2 is Trp, Gly, Lys or Arg, Xaa in position 3 is lie, Leu, Val or Met Xaa in position 4 is lie, Val or Leu Xaa in position 5 is Leu, Met, Val or Pro Xaa in position 12 is Arg, Lys Xaa in position 13 is Met or Leu, Xaa in position 15 is Ser, Cys or Gin, Xaa in position 17 is Thr, Val, lie, Ser or Ala, Xaa in position 18 is Ser, Gly or Thr, Xaa in position 21 is Asp, Glu, Cys or Gly, Xaa in position 22 is Gly or none wherein n 0, 1, 2 or 3, Xaai Xaa 2 Xaa 3 Pro lie Pro Xaa 7 Xaas Xaa 9 Xaaio Xaan Xaa 12 [Gly]n Xaa 1 3 Xaa 14 Xaai 5 Xaais Xaai 7 Xaas 1 Xaa 19 Xaa 20 Xaa 21 Xaa 22 Xaa 23 Xaa 24 (SEQ ID NO: 9) W-0o"Mems Do0 Not Delete\Do ot delete. 2DOgtAmcendm ts\tRN788723 I SPA 280 109doC

O

8 wherein Xaa in position 1 is Asn, Ser, Gly, His, Ala, Pro, Arg or none O Xaa in position 2 is Asn, Ala or Lys Xaa in position 3 is Pro, Gin, Gly, Ile or Leu Xaa in position 7 is Val or Ala s Xaa in position 8 is Gly or Lys oo Xaa in position 9 is Glu, Asp, Lys, Phe or Thr S Xaa in position 10 is lie. Met, Val or Leu Xaa in position 11 is Tyr, Leu or none Xaa in position 12 is Ser or none Xaa in position 13 is Arg or none Xaa in position 14 is Asp, Arg, Trp, Ala or none Xaa in position 15 is lie or none Xaa in position 16 is Tyr or none Xaa in position 17 is Lys or Arg Is Xaa in position 18 is Arg, Lys or Asp Xaa in position 19 is Trp or Gly Xaa in position 20 is lie, Met, Val, Gin or Ala Xaa in position 21 is lie, Val or Ala Xaa in position 22 is Leu, Met or Val Xaa in position 23 is Gly or Cys Xaa in position 24 is Leu or none wherein the sequence of SEQ ID NO 9 consists of at least six consecutive amino acids and n 1,2 or 3, Xaa, Xaa 2 lie lie Xaa, Xaa 6 Xaa Xaae Xaa, Leu Xaa,, [Gly] [Arg]m Xaa 1 2 Xaa 1 Xaa 1 Xaas Xaa 8 Xaa, 1 Xaa,, Xaa 9 Xaa2 Xaa 2 Xaa2 Xaa3 Xaa 24 Xaa2 (SEQ ID NO: wherein the Xaa in position 1 is Pro, Lys, Arg or none Xaa in position 2 is Glu, Arg, Phe or Lys Xaa in position 5 is Pro or Thr Xaa in position 6 is Met, Thr or Nleu Xaa in position 7 is Phe or Leu N 9

O

N Xaa in position 8 is Ser, Thr, Ala or Met O Xaa in position 9 is Ala, Glu or Leu S Xaa in position 11 is Ser or none S Xaa in position 12 is Ala, Arg or none Xaa in position 13 is lie, Leu or none 00 Xaa in position 14 is Ser, Ala, Leu or none Xaa in position 15 is Tyr, Glu or Asp N Xaa in position 16 is Gly or Asp 0 Xaa in position 17 is Ala or Leu c to Xaa in position 18 is Thr, lie, Val, Leu or Asn, Xaa in position 19 is Pro, Thr or Ser Xaa in position 20 is Tyr, Phe, Nleu, His or Gin Xaa in position 21 is Asp. Asn, Leu or Ala Xaa in position 22 is Leu,. lie, Val or Asn is Xaa in position 23 is Asn, Tyr, Cys or Gly Xaa in position 24 is Thr, Met, lie, Ala, Val or none Xaa in postion 25 is Gly or none wherein the sequence of SEQ ID NO 15 consists of at least six consecutive amino acids, n 1,2 or 3 and m=0,1,2 or 3, the terminal ends of the sequences may be free carboxyl- or amino groups, amides, acyls, acetyls or salts thereof, two or more of the Cys residues may form part of an intrachain- or interchain disulphide binding, a -S-(CH 2 or a (CH 2 )p-bridge wherein p 1-8, optionally intervened by 2s one or more heteroatoms such as O, N or S and/or the said peptide sequences are immobilized to a solid support.

The new peptide sequences have the potential to serve as a good antigen wherein the antigen comprises at least one peptide selected from the group of sequences of SEQ ID NO SEQ ID NO 4, SEQ ID NO 9 or SEQ ID NO: 15. The antigenicity may be adapted through adjusting the ratio or concentration of different peptides or size of the peptides by for instance dimerisation or polymerisation and/or immobilisation to a solid phase. The antigen comprises two or more polypeptide sequences, according to the IND O C invention, which are either linked by a bridge for instance a disulphide bridge between S the Cys residues of the chains or bridges like C,-C 8 alkylen possibly intervened by one S or more heteroatoms like O. S, or N or preferably they are unlinked. The chains may be S immobilized to a solid phase in monomeric,dimeric or oligomeric forms. Further amino s acids may be added to the ends in order to achieve an «arms to facilitate immobilization.

00 oO All amino acids in the peptides of the invention can be in both D- or L-form, although the naturally occurring L- form is preferred.

OM 'o The C- and N-terminal ends of the peptide sequences could deviate from the natural sequences by modification of the terminal NH 2 -group and/or COOH-group, they may for instance be acylated, acetylated, amidated or modified to provide a binding site for a carrier or another molecule.

The peptides according to the invention are consisting of 6 to 50 amino acids, preferably between 10 and 30 amino acids. They are covering all natural variation of amino acids in the identified positions.

The polypeptide antigen according to the invention is either in a free or in a carrierbound form. The carrier or solid phase to which the peptide is optionally bound can be selected from a vide variety of known carriers. It should be selected with regard to the intended use of the immobilized polypeptide as a diagnostic antigen or as an immunizing component in a vaccine.

Examples of carriers that can be used for e.g. diagnostic purposes are magnetic beads or latex of co-polymers such as styrene-divinyl benzene, hydroxylated styrene-divinyl benzene, polystyrene, carboxylated polystyrene, beads of carbon black, non-activated or polystyrene or polyvinyl chloride activated glass, epoxy-activated porous magnetic glass gelatine or polysaccharide particles or other protein particles, red blood cells, mono- or polyclonal antibodies or fab fragments of such antibodies.

O

N According to a further embodiment of the present invention, the antigens may form part of a vaccine possibly combined with carriers, adjuvants or combined with other S immunostimulating elements such as canarypox virus carrying the env gene. Examples of carriers andlor adjuvants for vaccine purposes are other proteins such as human or s bovine serum albumin and keyhole limpet haemocyanin. Immunostimulatory materials 00 may be divided into three groups; adjuvants, carriers for antigens and vehicles.

S Examples of adjuvants include aluminum hydroxyd, aluminum salts, saponin, muramyl N di- and tri-peptides, monophosphoryl lipid A, B.pertussis and various cytokines 0 including the Thl cytokine IL-12 and IL-1. A number of protein toxins can be used to clN 1o carry passenger proteins across cellular membranes into the cytosol, which are useful in developing CTL vaccines. Carriers include bacterial toxoids such as inactivated tetanus and cholera toxins, genetically detoxified bacterial toxins such as heat labile enterotoxin from E.coli, fatty acids, live vectors such as polio chimeras and hybrid proteins that form particulates for example yeast retrotransposon hybrid TY particles is and HBcAg particles. Vehicles which are frequently occurring components in modem vaccines are consisting of mineral oil emulsion, Freunds complete and incomplete adjuvant, vegetable oil emulsions, nonionic block co-polymer surfactants, squalene or squalane, liposomes and biodegradable microspl)eres. Two novel adjuvants which possess significant potential for the development of new vaccines include an oil-inwater microemulsion (MF59) and polymeric microparticles. Any substance that can enhance the immunogenicity of the antigen may be used and several further alternatives of carriers or adjuvants are given in the US or European Pharmacopoeia.

A suitable formulation of the antigen for immunostimulatory uses may also comprise interferons such as INF-y, antiviral chemokines or haematopoietic growth factors such as granulocyte macrophage growth factor.

Another approach in order to enhance the stimulation and absorption in for instance the intestine is to administer the peptides of the invention, with small peptides such as ditri- or tetra peptides. These peptides can be administered in addition to or in combination with the peptides of the invention. Preferably the peptides are administered together with the tripeptide YGG, consisting of amino acids in the D- or L-forms preferably in the D-form.

O

12 Recent approaches to non-parenteral delivery of vaccines, for instance via mucosa 0 include; gene fusion technology to create non-toxic derivatives of mucosal adjuvants, Z genetically inactivated antigens with a deletion in an essential gene, coexpression of an S antigen and a specific cytokine that is important in the modulation and control of a s mucosal immune response, and genetic material itself that would allow DNA or RNA 00 uptake and its endogenous expression in the host's cells.

One approach for developing durable responses where cell-mediated immunity is required, is to vaccinate with plasmid DNA encoding one or more specific antigen(s).

In order to protect against HIV infection, vaccines should induce both mucosal and systemic immune responses and could be administered by any convenient route, parenterally or non-parenterally, such as subcutanously, intracutanously, intravenously, intramuscularly, perorally, mucosally or intranasally for example.

In a preferred embodiment of the vaccine according to the present invention it comprises antigens containing the peptides of theSEQ ID NO 1, 4, 9 and 15, more preferred the peptides occur in the ratio 1:1:1:1.

In a further preferred embodiment the vaccine composition contains the antigens; RAL GPAATLQTPWTASLGVG-NH,(SEQIDNO: 3 RWLL LGLNPLVGGGRLYSPTSILG-NH,(SEQIDNO: 6 RAI P I PAGTLLSGGG RAIY KRTAI LG-NH2(SEQ ID NO: 11) and RFIIP NIFTALSGG R RALLYGATPYAIG-NH (SEQ IDNO:18).

One of the sequences contains a B-cell epitope and will activate the humoral immune system, whereas the other sequences contribute with CTL-epitopes and the amino acid changes implemented within the frame of the CTL-epitope are designed to achieve enhanced binding. Other amino acid changes have been conducted in order to facilitate the synthesis of the peptide and/or increase the solubility of the peptide.

A method for detecting antibodies, induced by HIV-1 or HIV-1 specific peptides or S proteins, in a sample of body fluid using the present antigens is a further embodiment of S the invention. Also immunoassay kit designed for this detection and antibodies capable of selectively reacting with the said antigens are encompassed by the present s invention.

00 DESCRIPTION OF THE PREPARATION OF THE PEPTIDES 0 The peptides of the invention can be produced by any known method of producing a io linear amino acid sequence, such as recombinant DNA techniques. A nucleic acid sequence which encodes a peptide of the invention or a multimer of the said peptides, is introduced into an expression vector. Suitable expression vectors are for instance plasmids, cosmids, viruses and YAC (yeast artifical chromosome) which comprise necessary control regions for replication and expression. The expression vector may be stimulated to expression in a host cell. Suitable host cells are for example bacteria, yeast cells and mammal cells. Such techniques are well known in the art and described for instance by Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, 199. Other well-known techniques are degradation or synthesis by coupling of one amino acid residue to the next one in liquid phase or preferably on a solid phase (resin) for instance by the so-called Merrifield synthesis. See for instance Barany and Merrifield in the Peptides, Analysis, Synthesis, Biology, Vol.2, E. Gross and Meinhofer, Ed. (Acad.Press, 1980), Kneib-Coronier and Mullen Int. J. Peptide Protein Res.,30, p.705-739 (1987) and Fields and Noble Int.J.Peptide Protein Res., 35, p.161-214 (1990).

In case a linked or cyclic peptide is desired, the amino acid sequence is subjected to a chemical oxidation step in order to cyclize or link the two cysteine residues within one or between two peptide sequences, when the appropriate linear amino acid sequences are synthesized, see Akaji et al., Tetrahedron Letter, 33, 8, p.1073-1076, 1992.

O 14 GENERAL DESCRIPTION OF SYNTHESIS

O

All peptide derivatives prepared in the Examples given below were synthesized on a Milligen 9050 Peptide Synthesizer using a standard program. The resin used was Tenta Gel P RAM with a theoretical loading of 0,20 meq/g (RAPP POLYMERE GmbH, OC Tubingen). The final product of the synthesis was dried in vacuo ovemight. The peptide Swas then cleaved from the resin by treatment with 90% trifluoroacetic acid in the: Spresence of ethandithiol and water as scavengers (1,5 hours at RT). Then Sthe resin was filtered and washed on filter with additional trifluoroacetic acid (100%) (2 x so 20 ml). The combined filtrates were evaporated in vacuo (water bath at RT) and the residue was triturated with ethyl ether (200 ml) and the precipitated product filtered off.

The solid was promptly dissolved on filter with glacial acetic acid (100 ml) and added to I of 20% acetic acid in methanol and treated with 0,1 M solution of iodine in methanol until a faint brown colour remained. Then Dowex 1 x 8 ion exchange in s1 acetate form (15g) (Bio-Rad, Richmond, CA) was added and the mixture filtered. The filtrate was evaporated and the residue freeze-dried from acetic acid. The product was then purified by reversed phase liquid chromatography on a column filled with Kromasile 100 5 C8 (EKA Nobel, Surte, Sweden) in a suitable system containing acetonitrile in 0,1 trifluoroacetic acid water solution. The samples collected from the column were analyzed by analytical high performance liquid chromatography (HPLC) (Beckman System Gold, USA) equipped with a Kromasil® 100 5 C8 Column (EKA Nobel, Surte, Sweden). Fractions containing pure substance were pooled, the solvent was evaporated and the product freeze-dried from acetic acid. The final HPLC analysis was performed on final product, and the structure of the peptide was confirmed by amino acid analysis and mass spectrometry (LDI-MS).

All amino acids used during the synthesis were L-amino acids and they were protected with a fluorenylmethoxy-carbonyl group at the ot-amino function. The side chains were protected as follows: Cys (Trt), Gin(Trt), Glu(OtBu), Thr(tBu).

The abbreviations, within the brackets are

IND

O

Trt triphenylmethyl S t-Bu =tert. Butyl S OtBu tert. Butylester The amino acid derivatives was supplied by Bachem AG, Switzerland.

Os EXAMPLE 1 S Preparation of K A L G P G A T L Q TP WT A C Q G V G NH 2 (SEQ ID NO: 2).

The peptide was synthesized in amide form, from corresponding starting materials O according to the general description of synthesis. The purity was determined by HPLC o analysis and the structure was confirmed by amino acid analysis and mass spectrometry (LDI-MS).

Purity (HPLC)- 87 EXAMPLE 2 s PreparationofRALGPAATL Q TPWTASL G V G (SEQ ID NO 3).

The peptide was synthesized in amide form, from corresponding starting materials according to the general description of synthesis. The purity was determined by HPLC analysis and the structure was confirmed by amino acid analysis and mass spectrometry (LDI-MS).

to Purity (HPLC): more than Molecular weight (free base): 1966 Molecular formula: CaH,Oz 2 N2 EXAMPLE 3 2 Preparation ofW I P G L N P LVG G G KLY S P T S I LCG-NH (SEQ IDNO The peptide was synthesized in amide form, from the corresponding starting materials according to the general description of synthesis. The purity was determined by HPLC analysis and the structure was confirmed by amino acid analysis and mass spectrometry (LDI-MS).

Purity (HPLC): Mass spectral analysis Theoretical molecular weight: 2454.9 Experimental molecular weight: 2454.8 ES+ EXAMPLE 4 S PreparationofRWLLLGLNPLVGGG R LYSPTSILG(SEQIDNO: 6 M The peptide was synthesized in amide form, from the corresponding starting materials according to the general description of synthesis. The purity was determined by HPLC s analysis and the structure was confirmed by amino acid analysis and mass 00 spectrometry (LDI-MS).

nm Purity (HPLC): more than 95 IND Molecular weight (free base): 2552 Molecular formula: C,,9H,sO 2 N33 EXAMPLE Preparationof KILLGLNPLVGGGRLYSPTSILG(SEQIDNO:7),RLL LGLNPLVGGGRLYSPTTILG(SEQIDNO:8)andNIPIPVGDIYGG G D I Y K R W Q A L C L (SEQ ID NO 24). The peptides are synthesized in amide s1 form, from the corresponding starting materials according to the general description of synthesis. The purity are determined by HPLC analysis and the structures are confirmed by amino acid analysis and mass spectrometry (LDI-MS).

EXAMPLE 6 Preparation of R N I P I PVG D I YGG G D I Y K R WQ A LCL (SEQ IDNO: The peptide was synthesized in amide form, from the corresponding starting materials according to the general description of synthesis. The purity was determined by HPLC analysis and the structure was confirmed by amino acid analysis and mass spectrometry (LDI-MS).

Purity (HPLC): 85 Mass spectral analysis Theoretical molecular weight: 2817.3 Experimental molecular weight: 2813.7 ES+ EXAMPLE 7 Preparation of RAl P I PAGTLLS G GG R A I Y KRWA I L G (SEQ ID NO: 11).

The peptide was synthesized in amide form, from the corresponding starting materials according to the general description of synthesis. The purity was determined by HPLC S analysis and the structure was confirmed by amino acid analysis and mass 0 S spectrometry (LDI-MS).

M Purity (HPLC): more than 95 Molecular weight (free base): 2707 Molecular formula: C,,H2ON, 00 EXAMPLE 8 I0 Preparation of AL P I PA G F I Y G G G R IY K R WQAL G (SEQ ID NO 12). K I P SI PVG F I G GW IYKRWAI L G (SEQ ID NO: 13) and K I P V G T L L S GG o G R I Y K R WA I L G SEQ ID NO: 14). The peptides are synthesized in amide form, from the corresponding starting materials according to the general description of synthesis. The purity are determined by HPLC.analysis and the structures are confirmed by amino acid analysis and mass spectrometry (LDI-MS).

1 EXAMPLE 9 Preparation of K F II P NI F S A L G GA I S Y D L N TNI L N C I (SEQ ID NO 16).

The peptide was synthesized in amide form, from the corresponding starting materials according to the general description of synthesis. NI in the sequence is Norleucine. The purity was determined by HPLC analysis and the structure was confirmed by amino acid analysis and mass spectrometry (LDI-MS).

Purity (HPLC) more than 80 Mass spectral analysis Theoretical molecular weight: 2783.3 Experimental molecular weight: 2783.3 ES+ EXAMPLE Preparation ofKF IIP NI F SALS G G G A I S Y D L N T F L N C I G (SEQ ID NO 17).

Purity (HPLC) more than 80 Mass spectral analysis Theoretical molecular weight: 2932.4 18

C

Experimental molecular weight: 2931.8 ES+ 0 EXAMPLE 11 S PreparationofRFIIP

NIFTALSGGRRALLYGATPYAIG(SEQIDNO:

s 18).

oO The peptide was synthesized in amide form, from the corresponding starting materials S according to the general description of synthesis. NI in the sequence is Norleucine. The N purity was determined by HPLC analysis and the structure was confirmed by amino acid analysis and mass spectrometry (LDI-MS).

o0 Purity (HPLC): more than 95 Molecular weight (free base): 2894 Molecular formula: C, 3 7

H,,

2 7

ON

37 EXAMPLE 12 is Preparation of K II P NI F S A L G G GR L L Y GATP Y A I G (SEQ ID NO 19), RI I P NI FTALS G G GRL LY G ATP YAIG (SEQ ID NO :20) and WI I P NI F SA LG G A I SY D L N T NIL N C I (SEQ ID NO: 25). The peptides are synthesized in amide form, from the corresponding starting materials according to the general description of synthesis. The purity are determined by HPLC analysis and the structures are confirmed by amino acid analysis and mass spectrometry (LDI-MS).

EXAMPLE 13 Dimerisation via disulphide bridge.

The peptide sequences of the Examples 1 and 3 were linked via an oxidation step to form a dipeptide wherein the cysteine residues formed a disulphide bridge. The bridge was formed in either ways; A) Oxidation with I2. Equal amounts of the peptides were dissolved in acetic acid/methanol and 0.1 M 12 in methanol was added yielding a mixture of the dimer.

or B) Oxidation via [Cys(Spy) 1 6]-SEQ ID NO 2. 2,3mM of the peptide of SEQ ID NO 2 dissolved in 2 M AcOH (aq) and 2-propanol was treated with 2,2 dithiodipyridin (3 eqv) to yield [Cys(Spy)']-SEQ ID NO 2. Equal amounts of [Cys(Spy)' 6 ]-SEQ ID NO 2 and peptide of SEQ ID NO 5 were dissolved in 10 mM NH 4 Oac (aq pH=6, 5) and methanol to yield the dimer of SEQ ID NO 21.

The purity of the peptide was determined by HPLC analysis and the peptide structure s was confirmed by amino acid analysis. The peptide content (aminoacid free base) was Purity (HPLC): 92%.

EXAMPLE 14 o0 A vaccine comprising the peptides of the SEQ ID NO 3, 6, 11 and 18 was prepared.

The freeze-dried peptides were dissolved in sterile water at a final concentration of 4 mg/ml. The final salt concentration was 0,9 A preparation of a granulocytemacrophage-colony stimulating factor (GM-CSF) was also prepared, according to the manufacturers directions for use, to a final concentration of 0.3 mg/ml. The two is solutions are administered intracutaneously. A typical injection dose is 100 Pl.

EXAMPLE An antigen solution or suspension is mixed with equal parts of Freund's adjuvant of Behring, complete or incomplete, and is then finely emulsified by being drawn up into, and vigurously pressed out of, an injection syringe, or with a homogenator. The emulsion should remain stable for at least 30 minutes. The antigen-adjuvant emulsions is best injected subcutaneously as a depot.

EXAMPLE 16 Toxicity data.

The dipeptide of Example 13 was diluted in 0,9% NaCI to a test solution concentration of 4 mg/ml. The peptide was administered by injection to NMFI female mice in a dose of 100 pg per kg bodyweight. No toxicological effects were observed and the peptide was deemed not toxic.

Toxicity studies were performed in mice and rats on the peptide composition of the vaccine in Example 14. The mouse was selected for the study to provide comparative data from a second commonly used rodent species. The test substance was a mixture of four peptides supplied as one vial containing lyophilised material for reconstitution 0 with physiological saline, and dose levels were expressed in terms of total peptide load.

SThe individual peptides was present in ratio 1:1:1:1 giving dose levels of each peptide of 0.0075 mg/kg body weight, 0.075 mg/kg body weight and 0.75 mg/kg body weight, s which are up to 500 fold the intended human dose. The test animals were divided into 00 four groups of ten animals each (five males and five females); a saline control group m and groups for low, intermediate and high doses. The test composition was IO administered once, by intravenous infusion into a tail vein at a dose rate of 3 mllminute.

0 The animals were killed at day 15 and 16 by intraperitoneal injection of sodium pentobarbitone.

The results of these studies indicated that the dose levels administered to the mice and rats elicited no adverse reactions and that the no effect level was in excess of 3 mg/kg.

is EXAMPLE 17 Immunoassay for detection of antibodies induced by HIV-1.

The magnetic particle reagents are to be prepared according to the manufacturers recommended protocol. Dynal AS, is the manufacturer of the Dynabeads, which are employed. The magnetic particles coated with ligand are called Reagent 1. A peptide according to the invention is covalently coupled to the pre-activated surface of the magnetic particles. It is also possible to physically absorb the peptide to the surface of the magnetic particles. The concentration of particles in Reagent 1 is within the range from 1 mg/ml to 15 mg/ml. The particle size varies between 0.2 lm to 15 pm. The concentration of peptides is within the range from 0,01 mg/mg particle to 1 mg/mg particle.

The anti human Ig Alkaline Phosphatase (AP) conjugated antibody reagent is prepared according to the recommended protocol of Dako AS. This protocol is a standard procedure in this field. This reagent is called Reagent 2.

The substrate solution phenolphtalein-monophosphate is to be prepared according to the recommended protocol of Fluka AG. This protocol is a standard procedure in this field. The substrate solution is called Reagent 3.

N 2 1 I The washing and incubation buffer which is used is standard 0,05M tris-base buffer with O the following additional compounds; Tween 20 (0,01% to glycerol to and sodium chloride to S The assay procedure comprises an incubation step wherein 1 drop of Reagent 1 is s mixed with 2 drops of washing buffer in each well. After mixing, 30 I 1 of sample is CO added and the solution is incubated for 5 minutes. The magnetic particles can be trapped by a magnet and the liquid removed, before the magnet is separated. Then the i wells are washed twice in 4 drops of washing solution, before incubation with Reagent 2. 1 drop of Reagent 2 is added with 2 drops of washing buffer and the solution is io incubated for 5 minutes. The magnetic particles can be trapped by a magnet and the liquid removed, before the magnet is separated. Then the washing step is repeated before incubation with Reagent 3. 2 drops of Reagent 3 is added to each well and the solution is incubated for 3 minutes. The results can be read against a white background. Positive results are red strong red) whereas negative results are s1 clearly light yellow/brown solutions as obtained in the negative control.

The immunoassay kit could be used in detection of antibodies, induced either by HIV virus or HIV-specific peptides or proteins, for instance the peptides of the present invention.

The above Examples are only meant as illustrating the invention. It must be understood that a person skilled in the art can modify the peptides, antigens and vaccines herein described without deviating from the concept and scope of this invention as set forth in the claims.

The polypeptides of the invention can be used in a combination of at least one peptide selected from each group of sequences, SEQ ID NO 1, SEQ ID NO 4, SEQ ID NO: 9 and SEQ ID NO: 15 to form antigens and the the active principle of a prophylactic or therapeutic vaccine intended to provide protection against the human immunodeficiency virus type 1 (HIV-1). The vaccine may include compounds having beneficial effects in protecting or stimulating the host's immune system (human being or vertebrate animal) for instance interleukins, interferons, granulocyte macrophage growth factors, haematopoietic growth factors or similar. Preferably the vaccine O 22 composition further contain an adjuvant or vehicle, more preferably the adjuvant or 0 vehicle is Monophosphoryl Lipid A (MPL possibly with alum, Freund's adjuvant (complete or incomplete) or aluminum hydroxyd. The optimal amount of adjuvant/vehicle will depend on the type(s) which is chosen.

s The peptide or vaccine formulation can be freeze-dried prior to storage. The vaccine S may be stored preferably at low temperature, in ampoules containing one or more S dosage units, ready for use. A typical dosage unit of the peptide according to the invention is within the concentration range 1 pg-1mg per kg bodyweight, preferably within 2 pg-0.15 mg per kg body weight. Persons skilled in the art will appreciate that a suitable dose will depend on the body weight of the pasient, the type of disease, severity of condition, administration route and several other factors. The vaccine might be administered up to twelve times and through injection, typically it will be administered about three times. In preparation of an injection solution the peptides are dissolved in sterile sodium chloride solution at a final concentration of 1 mg/ml per is peptide and 0,9% sodium chloride. Typically an injection volume is 100 !l to 200 pl (2 x 100 pl). The peptide is preferably co-administered with a suitable adjuvant and/or a granulocyte-macrophage growth factor for instance Leucomax® aShering Plough>.

Suitable administration may be intracutane, subcutane, intravenous, peroral, intramuscular, intranasal, mucosal or any other suitable route. Booster administrations may be required in order to maintain protection. For persons skilled in the art it will be understood that the vaccine compositions according to the invention are useful not only in prevention of infection, but also in treatment of infection.

Claims

1. A peptide derived from HIV gag p24 protein, wherein the peptide comprises a O 5 modified amino acid sequence containing modifications compared to the native sequence and comprising the amino acid sequence: 00 0' Xaa, Xaa 2 Xaa 3 Xaa 4 Xaas Gly Leu Asn Pro Leu Val [Gly]n Xaa 12 Xaa 13 Tyr Xaas Pro k' Xaa1 7 Xaa 18 lie Leu Xaa 2 1 Xaa 22 (SEQ ID NO: 4) N Swherein the amino acids of the chain could have the following meanings: C Xaa in position 1 is Arg, Lys, Asp or none, Xaa in position 2 is Trp, Gly, Lys or Arg, Xaa in position 3 is lie, Leu, Val or Met, Xaa in position 4 is lie, Val or Leu, Xaa in position 5 is Leu, Met, Val or Pro, Xaa in position 12 is Arg, or Lys Xaa in position 13 is Met or Leu, Xaa in position 15 is Ser, Cys or Gin, Xaa in position 17 is Thr, Val, lie, Ser or Ala, Xaa in position 18 is Ser, Gly or Thr, Xaa in position 21 is Asp, Glu, Cys or Gly, Xaa in position 22 is Gly or none Wherein n 1, 2 or 3, and the terminal ends of the sequences may be free carboxyl- or amino groups, amides, acyls, acetyls, or salts thereof, two or more of the Cys residues may form part of an intrachain- or interchain disulphide binding, a -S-(CH 2 or a -(CH2)p- bridge wherein p 1-8 optionally intervened by one or more heteroatoms such as O, N and S and/or the said peptide sequences are immobilized to a solid support. W.docrnmentslo Not OefelteDo not delste 2009gA.neen otsrURN786723 ISPA 280109doc IO 0 2. A peptide according to claim 1, wherein the amino acid sequence of SEQ ID NO:4 is selected from the group of SEQ ID NO:5, SEQ ID NO:6, SEQ ID O Z NO:7, and SEQ ID NO:8.

3. An antigen comprising at least one peptide according to claims 1 or 2.

4. An antigen according to claim 3, wherein the antigen comprises at least 00 0 one peptide selected from the peptides of SEQ ID NO:4. 0 5. A vaccine composition, wherein the vaccine comprises an antigen O 10 according to claims 3 or 4 with a pharmaceutically acceptable diluent and optionally an adjuvant, carrier and/or vehicle and optionally immunostimulatory compound(s).

6. A vaccine composition according to claim 5, wherein the vaccine comprises at least one peptide selected from the peptides of SEQ ID NO:4.

7. A vaccine composition according to claim 6, wherein the vaccine comprises the peptides of SEQ ID NO:6.

8. A vaccine composition according to any one of claims 5 to 7, wherein the peptides are dissolved in a saline water solution and the optional immunostimulatory compound is a granulocyte macrophage growth factor.

9. A vaccine composition according to any one of claims 5 to 8, wherein the composition comprises an adjuvant selected from the group Monophosphoryl Lipid A Freund's complete or incomplete adjuvant or aluminium hydroxyd. A method of detecting antibodies, induced by a HIV or HIV-specific peptides or proteins, in a sample of body fluid, wherein the method includes subjecting the said sample to an immunoassay, wherein the antigen(s) is/are selected from the peptides according to claims 1 or 2.

11. An immunoassay kit for the detection of antibodies, induced by a HIV or O Z HIV-specific peptides or proteins, in a sample of body fluid, wherein the kit includes a diagnostic antigen that is a peptide according to claims 1 or 2. 0 12. A peptide according to claim 1, substantially as hereinbefore described 00 0 with reference to any of the Examples. IN ^sD 0 26 O SEQUENCE LISTING s GENERAL INFORMATION: S(i) APPLICANT (for all countries except US): 0 NAME: BionorA/S n STREET: Stremdalsjordet 4, P.O.Box 1868 Gulset o CITY: Skien O COUNTRY: Norway POSTAL CODE (ZIP): N-3705 TELEPHONE:.+47 35 50 57 s. TElEFAX: 47 35 50.57 01 INVENTOR AND APPUCANT(for US only) NAME: Birger Sorensen STREET: Meieria 3 CTY: 3727 Skien COUNTRY Norway (ii) TITLE OF INVENTION: HIV Peptides, antigens, vaccine compositions, immunoassay and a method of detecting antibodies induced by HIV. (iii) NUMBER OF SEQUENCES: (iv) COMPUTER READABLE FORM: MEDIUM TYPE: Floppy disk COMPUTER: IBM Compatible 2s OPERATING SYSTEM: Windows SOFTWARE: Word CURRENT APPLICATION DATA: Priority from NO 1999 1078 filed.4 March 2000 APPLICATION NUMBER: INFORMATION FOR SEQ ID NO:1: SEQUENCE CHARACTERISTICS: LENGTH: 20 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: both (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: No S(v) FRAGMENT TYPE: internal S(ix) FEATURE: s NAME/KEY: Modified-site LOCATION: 1 0 OTHER INFORMATION: /note= "Xaa in position 1 is Lys or Arg 00 ix) FEATURE: 0 NAME/KEY: Modified-site N LOCATION: 2 I OTHER INFORMATION: /note="Xaa in position 2 is Ala, Gly, Ser or Arg. cN ix) FEATURE: Is NAME/KEY: Modified-site LOCATION: 3 OTHER INFORMATION: /note=" Xaa in position 3 is Leu or Met ix) FEATURE: 2o NAME/KEY: Modified-site LOCATION: 4 OTHER INFORMATION: /note= Xaa in position 4 is Gly or Arg ix) FEATURE: 2s NAME/KEY: Modified-site LOCATION: or Ala(D) OTHER INFORMATION: /note=" Xaa In position 5 is Pro, Thr, Val, Ser, Gin ix) FEATURE: o NAME/KEY: Modified-site LOCATION: 6 or Glu(D) OTHER INFORMATION: /note= "Xaa in position 6 is Gly, Ala, Lys, Arg, Gin ix) FEATURE: as NAME/KEY: Modified-site LOCATION: 8 OTHER INFORMATION: /note= Xaa in position 8 is Thr or Ser ix) FEATURE: NAME/KEY: Modified-site LOCATION: 9 OTHER INFORMATION: /note= "Xaa in position 9 is Leu or lie ix) FEATURE: NAME/KEY: Modified-site LOCATION: 14 OTHER INFORMATION: /note= "Xaa in position 14 is Thr,Ser or Val ix) FEATURE: so NAME/KEY: Modified-site LOCATION: OTHER INFORMATION: /note=" Xaa in position 15 is Ala or Ser ix) FEATURE: NAME/KEY: Modified-site, LOCATION: 16 00 OTHER. INFORMATION: inote="Xaa in position 16 is Cys or Ser, optionally C Cys forms part of a disulphide -bond N 10 i;x) FEATURE: NO NAME/KEY: Modified-site LOCATION: '17 ri D) THE INQRM11O:/note="Xa in position 17 Is Gin or Leu. is ix) FEATURE: NAME/KEY: Modified-site. (B):LQCATION: 18 OTH ER INFORMATION: /note= Xaa in position 18 is Gly, Glu or Arg zD ix) FEATURE: NAME/KEY: Modified-site LOCATION: OTHER INFORMATION: /note=" Xaa in position 20 is Gly-or A .rg (Xi) SEQUENCE DESCRIPTION: SEQ ID NO:1: Xaa, Xaa, 2 Xaa',Xaa 4 Xaa,, Xaa 6 Ala Xaa, Xaa -Gin Thr Pro Trp Xaa, 4 Xaa 1 5 Xaa 16 Xaa 17 15 10 Xaa 18 VaI Xaa2, 3s INFORMATION FOR SEQ ID NO:2: SEQUENCE CHARACTERISTICS: LENGTH: 20 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: both (ii MOLECULE TYPE: peptide 4s (iii) HYPOTHETICAL: No ix) FEATURE: NAME/KEY: Modified-site LOCATION: 16 OTHER INFORMATION: Inote= "Optionally Cys in position 16 forms part of a disulphide bond (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2: Lys Ala Leu Gly Pro Gly Ala Thr Leu Gin Thr Pro Trp Thr Ala Cys Gin Gly Val Gly 1 5 10 15 INFORMATION FOR SEQ ID NO:3: SEQUENCE CHARACTERISTICS: LENGTH: 20 amino acids as TYPE: amino acid SANDEDNESS: single TOPOLOGY: both (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: No (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3: Arg Ala Leu Gly Pro Ala Ala Thr Leu Gin Thr Pro Trp Thr Ala Ser Leu Gly Val Gly 1 5 10 15 INFORMATION FOR SEQ ID NO:4: SEQUENCE CHARACTERISTICS: LENGTH: 23-24 amino acids 3s TYPE: amino acid STRANDEDNESS: single (D).TOPOLOGY: both (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: No (ix) FEATURE: NAME/KEY: Modified-site 4s LOCATION: 1 OTHER INFORMATION: /note= Xaa in position 1 is Arg, Lys, Asp or none (ix) FEATURE: NAME/KEY: Modified-site so LOCATION: 2 O OTHER INFORMATION: /note= Xaa in position 2 is Trp, Gly, Lys orArg S (ix) FEATURE: m NAME/KEY: Modified-site "s LOCATION: 3 OTHER INFORMATION: /note= "Xaa in position 3 is lie, Leu, Val or Met 00 ix) FEATURE: S(A) NAME/KEY: Modified-site Sto LOCATION: 4 S(D) OTHER INFORMATION: /note= Xaa in position is le, Val or Leu 0. ix) FEATURE: S(A) NAME/KEY: Modified-site is LOCATION: OTHER INFORMATION: /note= Xaa in position 5 is Leu, Met, Val or Pro ix) FEATURE: NAME/KEY: Modified-site LOCATION: 12 OTHER INFORMATION: /note= Xaa in position 12 is Arg or Lys ix)-FEATURE: NAME/KEY: Modified-site 2' LOCATION: 13 OTHER INFORMATION: /note=" Xaa in position 13 is Met or Leu ix) FEATURE: NAME/KEY: Modified-site LOCATION: OTHER INFORMATION: /note= Xaa in position 15 is Ser, Cys or Gin, optionally Cys forms part of a disulphide-bond ix) FEATURE: 3s NAME/KEY: Modified-site LOCATION: 17 OTHER INFORMATION: /nbte=" Xaa in position 17 is Thr, Val, lie, Ser or Ala ix) FEATURE: NAME/KEY: Modified-site LOCATION: 18 OTHER INFORMATION: /note= Xaa in position 18 is Ser, Gly or Thr ix) FEATURE: 4A NAME/KEY: Modified-site LOCATION: 21 OTHER INFORMATION: /note= Xaa in position 21 is Asp,Glu, Cys or Gly, optionally Cys forms part of a disulphide-bond A x) FEATURE: NAME/KEY: Modified-site (B),LOCIATION: 22 OTHER INFORMATION: /note= Xaa in position 22 is Gly or none ix) FEATURE-, NAM1E/KEY: Modified-site (B3) LOCATION: 11..1.2 OTHER INFORMATION: /note= "optionally inserted Gly-bridge of 0,1,2 or 3 i0 residues (xi) SEQUENCE* DESCRIPTION: SEQ ID NO*4 XaaXaa 2 :Xaa 3 Xaa 4 Xaa, Gly1eu Asn Pro Leu Val [GIyJLXaa 12 Xaa 1 3 Tyr Xaa,, Pro 'S *15 10 Xaa,., Xaa 16 lR6 Leu Xaa 21 Xaa22 ()INFORMATION FOR SEQ ID SEQUENCE CHARACTERISTICS: 2S LENGTH: 24 amnino acids TYPE: 'amino acid STfAANDEDNESS: single TOPOLOGY: both (1i) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: No ix) FEATURE: 3S NAME/KEY: Modified-site LOCATION: 23 OTHER INFORMATION: /note= Cys in position 23 may forms part of a disulphide bridg~e (xi) SEQUENCE DESCRIPTION: SEQ ID Trp Ile Ile Pro Gly Leu Asn Pro Leu Val Gly Gly Gly Lys Leu Tyr Ser Pro Thr Ser Ile Leu 10 15 CysG~ly INFORMATION FOR SEQ ID NO:6: so SEQUENCE CHARACTERISTICS: O 32 LENGTH: 24 amino acids TYPE: amino acid Z STRANDEDNESS: single m TOPOLOGY: both (ii) MOLECULE TYPE: peptide 00 (iii) HYPOTHETICAL No a o (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6: 0 Arg Trp Leu Leu Leu Gly Leu Asn Pro Leu Val Gly Gly Gly Arg Leu Tyr Ser Pro Thr'Ser 1 5 10 15 s e Leu Gly INFORMATION FOR SEQ ID NO:7: SEQUENCE CHARACTERISTICS: LENGTH: 23 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: both (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: No JO (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7: Lys lie Leu Leu Gly Leu Asn Pro Leu Val Gly Gly Gly Arg Leu Tyr Ser Pro Thr-Ser lie 1 5 10 15 Leu Gly INFORMATION FOR SEQ ID NO: 8 SEQUENCE CHARACTERISTICS: LENGTH: 23 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: both (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: No O 33 S (xi) SEQUENCE DESCRIPTION: SEQ ID NO:8 S Arg Leu Leu Leu Gly Leu Asn Pro Leu Val Gly Gly Gly Arg Leu Tyr Ser Pro Thr Thr lie S 1 5 10 15 Ss Leu Gly 00 INFORMATION FOR SEQ ID NO: 9 Sto SEQUENCE CHARACTERISTICS: LENGTH: 22-26 amino acids TYPE: amino acid O STRANDEDNESS: single TOPOLOGY: both (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL No ix) FEATURE: NAME/KEY: Modified-site LOCATION: 1 OTHER NFORMATION: note= Xaa in position is Asn, Ser, Gly His, Ala, Pro, Arg orDone ix) FEATURE: NAME/KEY: Modified-site LOCATION: 2 OTHER INFORMATION: /note=" Xaa in position 2 is Asn ,Ala or Lys ix) FEATURE: NAME/KEY: Modified-site LOCATION: 3 OTHER INFORMATION: /note= Xaa in position 3 is Pro, Gin, Gly, lie or Leu ix) FEATURE: NAME/KEY: Modified-site LOCATION: 7 OTHER INFORMATION: /note= Xaa in position 7 is Val or Ala ix) FEATURE: NAME/KEY: Modified-site LOCATION: 8 OTHER INFORMATION: /note= Xaa in position 8 is Gly, or Lys ix) FEATURE: NAME/KEY: Modified-site LOCATION: 9 S(D) OTHER INFORMATION: /note= Xaa in position 9 is Glu, Asp, Lys, Phe or so Thr O ix) FEATURE: Z NAME/KEY: Modified-site n LOCATION: s OTHER INFORMATION:note=" Xaa in position 10 is lie, Met, Val or Leu o ix) FEATURE: 00 NAME/KEY: Modified-site LOCATION: 11 Sl OTHER INFORMATION: /note= "Xaa in position 11 is Tyr, Leu or none I ix) FEATURE: O NAME/KEY: Modified-site (B)LOCATION:12 as OTHER.INFORMATION: Inote= "Xaa in position 12 is Ser or none ix) FEATURE: NAME/KEY: Modified-site LQCATION: 13 OTHER INFORMATION: /note= "Xaa in position 13 is Arg or none ix) FEATURE: NAME/KEY: Modified-site LOCATION: 14 S one OTHER INFORMATION: /note=" Xaa in position 14 isAsp. Arg, Trp, Ala or none. ix) FEATURE: NAME/KEY: Modified-site LOCATION: OTHER INFORMATION: /note= Xaa in position 15 is lie or none ix) FEATURE: NAME/KEY: Modified-site 3s LOCATION: 16 OTHER INFORMATION: /note= "Xaa in position 16 is Tyr or none ix) FEATURE: NAME/KEY: Modified-site LOCATION: 17 OTHER INFORMATION: /note= "Xaa in position 17 is Lys or Arg. ix) FEATURE: NAME/KEY: Modified-site s4 LOCATION: 18 OTHER INFORMATION: /note= "Xaa in position 18 is Arg, Lys or Asp ix) FEATURE: NAME/KEY: Modified-site so LOCATION: 19 IND OTHER INFORMATION:.Inote= "Xaa in position 19 is Trp or Gly Z ix) FEATURE: NAMEIKEY:' Modified-site LOCATION: OTHER INFORMATION: /note=" Xaa in position 20 is lie, Met, Val, Gin or S Ala 00 S ix) FEATURE- (A).NAME/KEY: Modified-site LOCQ 'ATION: 21 IND OTHER INFORMATION: /note=" Xaa'in position 21 is Ilie, Val or Ala ix)FEATURE:" s NAME/KEY: Modified-site *(B3):11OCATION: 22 OThJER INFORMATION: /note= Xaa in position 22 is Leu, Met or Val ix) FEATURF,:. NAMEIKEY: Modified-site LOCA i TON: 23. oTf4ER. INFORMATION: /note= "Xaa in position 23 is Gly or Cys 13 ix) FEATURE: NAME/KEY: Modified-site LOCATION: 24 OTHER INFORMATION": /note= Xaa in position 24 is Leu or none o0 ix) FEATURE: NAME/KEY: Modified-site LOCATION:,12..13 OTHER INFORMATION: /note= ~'optionally inserted Gly-bridge of 1,2 or 3 residues. 3S (xi) SEQUENCE DESCRIPTION: SEQ ID NO:9 *Xaa, Xaa 2 Xaa 3 Pro lie Pro Xaa 7 Xaa, Xaa, Xaa 10 Xaa,, Xaa 1 2 [Gly], Xaa 1 3 Xa 4 Xaa 1 1510 Xaa 1 6 Xaa, 17 Xaa, 8 Xaa, 9 Xaa2O Xaa 2 l Xaa 2 Xaa23 Xaa 24 INFORMATION FOR SEQ ID NO: SEQUENCE CHARACTERISTICS: LENGTH: 25 -amino acids 51~ANEDNE$:single o (D):fQPOLQGY:- both "Ni H IPOTH2CAL- No bo FEATURE-- 00 'ER iN!VRMA11Ot Inte=,ACys hq posIton 24 nwyfornis pait of a Kx SMQUENOE-DESOHIP11N. SEQM 10:10 Leu Ley INiFORMTION FOR SEQ ID No.; 11 WU M4E VIARACTERISM.CS ~tEIGT#I28 umino acick (iIQ 46ILEWL TYPEpepUdf, (ill WpoTHEICAL N4o (xi) Sr4QUENCE DESCRIPION., SEQ ID No0:11 Arg Ala Its Pro lie Pro Ala Gty lbw Lou Lou $ei Gly Gly, (31y AMs Ala Ile Tyr Lywsrq Tip 1 610 1620 Ala Ie Lou Gly INFORMAflON FOR SEQ ID NO0.12 SEQUEN4CE CHARACTERISTICS: LENG11-I: 23 amn~o acids (ES) TYPE: amino acid STRANDEDNESS: single, TOP OLOGY-. bclh Mii MOLECULE TYPE: peptide *(iii) HYPOTHETICAL: No (xi) SEQUENCE DESCRIPTION: SEQ ID NO:12 00 Ala Leu Pro le Pro Ala Gly Phe lie Tyr Gly Gly Gly Arg lie Tyr. Lys krg Trp Gin Ala Leu 1 5 10, 15 io Gly INO 2) INFORMATION FOR.SEQMI NO:13 N- SEQUENCE CHARACTERISTICS: is LEN4GTH: .22- amino acids ()TYPE: amino acid* STRANDEDNESS: single TOPO6LOGY: bath zo* (i)V~OLECULE 1YPE-' peptide (iii) HYPOTHETICAL: No SEQDUENCE DESCRI.PTION: SEQ IDNO:13 Lys lie Pro Ilie Pro Val Gly Phe Ile Gly Gly Gly Tirp lie Tyr Lys Arg Tmp Ala lie Leu Gly 1 5 10 15 INFORMATION FOR SEQ, ID NO:14 SEQUENCE CHARACTERISTICS:. LENGTH: 24 amino acids TYPE: amino acid -STRANDEDNESS: single TOPOLOGY: both )i MOLECULE TYPE: peptide (iii) HYPOTHETICAL: No (xi SEQUENCE DESCRIPTION: SEQ ID NO:14 4S Lys lie Pro Ie Pro Val Gly Thr Leu Leu Ser Gly Gly Gly Arg Ile Tyr Lys Arg Tmp Ala Ilie 1 5 10 15 Leu Gly NO2 N- INFORMATION FOR SEQ ID NO:1 z SEQUENCE CHARACtTERISTICS: LENGTH:2

24-28 amino acids S TYPE: iamrnino aicid- (C S ADDNESS: single TOPOLOGY: Iboth 00 (iii) MOLECULE TYPE: pptide (iii) HYPOTHETICAL No 0 ix) FEATURE-, 6AMKEY:. Modified-site c-I is 6 ()CAIN1 OTHER INFORMATION: /note= Xaa in position. 1 s Pro. Lys. Arg or none ix) FEATURE:.- NAME/KEY: Modified-site LOCATION: 2. OTHERl INFORMATION: ]note=. Xaa -in position 2 is Glu, krg. Phe or Lys ix) FEATURE NAME/KEY: Modified-site OTHER. INFORMATION: /note= Xaa in position 5 is Pro or Thr ix) FEATURE: NAME/KEY:'Modified-site LOCATION: 6 OTHER INFORMATION: /note=" Xaa in position 6 Met, Thr or Nie ix) FEATURE: NAME/KEY: Modified-site LOCATION: 7 OTHER INFORMATION: /note= "Xaa in position 7 is Phe or Leu ix) FEATURE: NAME/KEY: Modified-site LOCATION: 8 OTHER INFORMATION: /note= "Xaain position 8 is Ser, Thr, Ala or Met ix) FEATURE. NAME/KEY: Modified-site LOCATION: 9 OTHER INFORMATION: /note= "Xaa in position 9 is Ala, Glu or Leu ix) FEATURE: NAME/KEY: Modified-site so LOCATION: 11 OTHER INFORMATION: /note=" Xaa in position 11 is Ser or none O ix) FEATURE: Z NAME/KEY: Modified-site s LOCATION: 12 OTHER INFORMATION:/note= Xaa in position 12 is Ala, Arg or none S ix) FEATURE: 0o NAME/KEY: Modified-site o LOCATION: 13 S(D) OTHER INFORMATION: Inote=" Xaa in position 13 is lie, Leu or none S ix) FEATURE: 0 NAME/KEY: Modified-site s LOCATION: 14 OTER INFORMATION: /note=" Xaa in position 14 is Ser, Ala, Leu or none ix) FEATURE: NAME/KEY: Modified-site to LOCATION: OTHER INFORMATION: /note=" Xaa in position 15 is Tyr, Glu or Asp ix) FEATURE: NAME/KEY: Modified-site S LOCATION: 16 OTHER INFORMATION: /note=" Xaa in position 16 is Gly or Asp ix) FEATURE: NAME/KEY: Modified-site 0 LOCATION: 17 OTHER INFORMATION: /note=" Xaa in position 17 is Ala or Leu ix) FEATURE: NAME/KEY: Modified-site LOCATION: 18 OTHER INFORMATION: /note= Xaa in position 18 is Thr, lie, Val, Leu or ix) FEATURE: 4o NAME/KEY: Modified-site LOCATION: 19 OTHER INFORMATION: /note= Xaa in position 19 is Pro, Thr or Ser ix) FEATURE: NAME/KEY: Modified-site LOCATION: Gin OTHER INFORMATION: /note= Xaa in position 20 is Tyr, Phe, Nie, His or Gin so ix) FEATURE: NAME.IKEY: Modified-site LOCATION: 21 OTHER INFORMATION: /note= "Xaa in position 21 is Asp, Asn, Leu or Ala s ix) FEATURE:. NAE/KEY: Modified-site LOCATIO0N:- 22 OTHE INFORMATION: /note=* Xaa in-Position 22 is Leu, lie, Val or Asn lo ix) FEATURE: NAME/KEY: Modified-site LOC ATION: 23 (D TERNF MAONIne=Xaa in position 23 Is Asn, Tyr, Cys or Gly Niis ix) FEATU RE: NAME/KEY: Modified-site -(E).LOCATION: 24 OTHi ER INFORMATION: /note= Xaa in position 24 is Thr, Met, lie, Ala, Val or none. ix) FEATURE: NAME/KEY: Mvodlifiedl-site LOCATI ON: OTHER INFORMATION: /note=" Xaa in position 25 is Gly or none. is ix) FEATURE:- NAME/KEY: Modified-site LOC ATION: 23 OTHER INFORMATION: /note= otoal Cys in position 23 forms part of a disulphidle-botid Lx) FEATURE:. NAME/KEY: Modified-site LOCATION:11I...1'2 OTAER INFORMATION: /note=" optionally a Gty-Arg bridge is inseited between Xaa 11 and 12, where n 2 and 3. and mn independenly of n is 0,1, 2 or 3. (xi) SEQUENCE DESCRIPTION: SEQ ID Xaa, Xaa 2 lie Ilie Xaa 5 Xaa 8 Xaa 7 Xaa, Xaa, Leu Xaa,, [Gly], [Arg],m Xaa 1 2 Xaa 13 Xaa 14 Xaaj, Xaae Xaa 17 r Xaa 18 Xaa,, Xaa., Xaa 2 1 Xaa22Xaa2 Xaa 2 4 Xaa~s 41 \O INFORMATION FOR SEQ ID NO:16 SEQUENCE CHARACTERISTICS: z LENGTH: 25 amino acids s TYPE: amino acid STRANDEDNESS: single TOPOLOGY: both g(ii) MOLECULE TYPE: peptide tl (iii) HYPOTHETICAL: No -0 ix) FEATURE: S(A) NAME/KEY: Modified-site Sis LOCATION: 24 OTHER INFORMATION: /note=" Cys in position 24 optionally forms part of a disulphide-bond (xi) SEQUENCE DESCRIPTION: SEQ ID NO:16 Lys Phe lie lie Pro Nle Phe Ser Ala Leu Gly Gly Ala lie Ser Tyr Asp Leu Asn Thr Nle 1 5 10 15 Leu Asn Cys le INFORMATION FOR SEQ ID NO:17 SEQUENCE CHARACTERISTICS: LENGTH: 28 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: both (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: No ix) FEATURE: NAME/KEY: Modified-site LOCATION: 26 OTHER INFORMATION: /note= "Cys in position 26 optionally forms part of a disulphide-bond (xi) SEQUENCE DESCRIPTION: SEQ ID NO:17 Lys Phe Ile lie Pro NIe Phe Ser Ala Leu Ser Gly Gly Gly Ala Ile Ser Tyr Asp Leu Asn 1 5 10 15 Thr Phe Leu Asn Cys lie Gly so (O INFORMATION FOR SEQ ID NO:18 Z SEQUENCE CHARACTERISTICS: n s LENGTH: 27 amino acids TYPE: amino acid STRANDEDNESS: single 0 TOPOLOGY: both 00 to (ii) MOLECULE TYPE: peptide S(iii) HYPOTHETICAL: No (xi) SEQUENCE DESCRIPTION: SEQ ID NO:18 Arg Phe lie lie Pro Nle Phe Thr Ala Leu Ser Gly Gly Arg Arg Ala, Leu Leu Tyr Gly Ala 1 5 10 15 Thr Pro.Tyr Ala lie Gly INFORMATION FOR SEQ ID NO:19 SEQUENCE CHARACTERISTICS: LENGTH: 24 amino acids 2 TYPE: amino acid STRANDEDNESS: single TOPOLOGY: both (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: No (xi) SEQUENCE DESCRIPTION: SEQ ID NO:19 Lys lie lie Pro Nle Phe Ser Ala Leu Gly Gly Gly Arg Leu Leu Tyr Gly Ala Thr Pro Tyr Ala 1 5 10 15 lie Gly INFORMATION FOR SEQ ID SEQUENCE CHARACTERISTICS: LENGTH: 25 amino acids TYPE: amino acid 4s STRANDEDNESS: single TOPOLOGY: both (ii) MOLECULE TYPE: peptide N (iii) HYPOTHETICAL: No 0 (xi) SEQUENCE DESCRIPTION: SEQ ID Arg Ie Ile.Pro NIe Phe Thr Ala Leu Ser Glly Gy Gly Arg Leu Leu Tyr GlyAla Thr Pro Tyr 1 5 10 15 O Ala Ile.Gly 00 0 c INFORMATION FOR SEQ ID N021 SEQUENCE CHARACTERISTICS: cI LENGTH: 44 amino adcids is TYPE: amino acid STRANDEDNESS: double TOPOLOGY: bofh. (ii) MOLECULE TYPE: dimeric peptide (iii) HYPOTHETICAL No ix) FEATURE: NAME/KEY: Modified-site 2s LOCATION: disulphide-bond between position 16 in SEQ ID NO: 2 and position 23 in SEQ ID NO: INFORMATION FOR SEQ ID NO:22 SEQUENCE CHARACTERISTICS: LENGTH: 40 amino acids TYPE: amino acid STRANDEDNESS: double TOPOLOGY: both (ii) MOLECULE TYPE: dimeric peptide (iii) HYPOTHETICAL: No ix) FEATURE: NAME/KEY: Modified-site LOCATION: disulphide-bond between position 16 in SEQ ID NO: 2 and position 16 in SEQ ID NO:2 OTHER INFORMATION: note=" INFORMATION FOR SEQ ID NO:23 SEQUENCE CHARACTERISTICS: NO 44 Cl LENGTH: -48 amino acids TYPE: amino acid z STRANDEDNESS: double TOPOLOGY: both MOLECULE TYPE: dimeric peptide 0 (iii) HYPOTHETICAL, No 00 kn D ix) FEATURE:. NAMEEY Modified-site 1-10 LOCATION: disulphide-bond between position 23 in SEQ ID NO: 5 an~d SpositiolMin SEQID NO: INFORMATION FOR SEQ ID NO:24: SEQUENCE CHARACTERISTICS: LENG *TH: 24 amino acids TYPE: amino acid o STRANDEDNESS: single TOPO6LOGY: both -MOLECULE TYPE: peptide (iii) HYPOTHEICAL- No ix) FEATURE: NAME/KEY: Modified-site LOCATION: 23 OTHER INFOR~mA-iON:*,/note= Csi oi"on2 a om ato disulphide bridge Csi oiin2 a om ato (xi) SEQUENCE DESCRIPTION: SEQ ID NO:24: Asn lie Pro -lie Pro Vat Gly Asp lie Tyr Gly Gly Gly Asp Ilie Tyr Lys Arg Tyr Gin Ala 1 5 10 15 Leu Cys Leu INFORMATION FOR SEQ ID SEQUENCE CHARACTERISTICS: LENGTH: '24 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: both (ii) MOLECULE TYPE: peptidle (iii) HYPOTHETICAL: No S ix),FEATURE: NAMEIKEY: Modified-site LOCATION: 23 OTHER INFORMATION: /note= WCys in position 23 optionally forms part of a 00 disulphide-bohd C*I 1 c-i (xi) SEQUENCE DESCRIPTION: SEQ ID N0:25 0Trp lie Ilie Pro Nle Phe Ser Ala Leu Gty..Gly Ala Ilie Ser Tyr Asp Leu Asn Thr NWe Cis 15 10 15 Leu Asn Cys Ilie